Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Ultragenyx Pharmaceutical : to Present at Jefferies Gene Therapy Summit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/01/2018 | 10:19am EST

NOVATO - Ultragenyx Pharmaceutical Inc.(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Jefferies Gene Therapy Summit on Thursday, September 27, 2018 at 8:00am ET in New York.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

Contact:

Danielle Keatley

Tel: 415-475-6876

(C) 2018 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ULTRAGENYX PHARMACEUTICAL
12:01pUltragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita fro..
AQ
02/14ULTRAGENYX PHARMACEUTICAL : and Kyowa Kirin Announce Positive 64-Week Results fo..
AQ
02/12ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Fourth Quarter and Full-..
PU
02/12ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Fourth Quarter and Full-..
AQ
02/04ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers (form..
AQ
02/04Ultragenyx Appoints Shehnaaz Suliman, M.D., to Board of Directors
GL
01/22ULTRAGENYX PHARMACEUTICAL : Announces Positive Topline Data from Ongoing Long-Te..
AQ
01/15ULTRAGENYX PHARMACEUTICAL INC. : Entry into a Material Definitive Agreement (for..
AQ
01/07ULTRAGENYX PHARMACEUTICAL INC. : Regulation FD Disclosure, Other Events, Financi..
AQ
01/07Flurry of management moves on eve of JPM
AQ
More news
Financials ($)
Sales 2018 49,6 M
EBIT 2018 -375 M
Net income 2018 -201 M
Finance 2018 286 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 50,7x
EV / Sales 2019 25,5x
Capitalization 2 805 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 72,4 $
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC27.55%2 805
GILEAD SCIENCES5.42%85 858
VERTEX PHARMACEUTICALS11.79%47 462
REGENERON PHARMACEUTICALS9.37%44 554
GENMAB-5.76%9 362
SAREPTA THERAPEUTICS INC23.60%9 013